Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension
- Nicole Pfarr1_1301, 2_1301Email author,
- Christine Fischer1_1301Email author,
- Nicola Ehlken2_1301,
- Tabea Becker-Grünig2_1301,
- Vanesa López-González3_1301,
- Matthias Gorenflo4_1301,
- Alfred Hager5_1301,
- Katrin Hinderhofer1_1301,
- Oliver Miera6_1301,
- Christian Nagel2_1301,
- Dietmar Schranz7_1301 and
- Ekkehard Grünig2_1301Email author
© Pfarr et al.; licensee BioMed Central Ltd. 2013
Received: 1 October 2012
Accepted: 26 December 2012
Published: 9 January 2013
Aim of this prospective study was to compare clinical and genetic findings in children with idiopathic or heritable pulmonary arterial hypertension (I/HPAH) with children affected with congenital heart defects associated PAH (CHD-APAH).
Prospectively included were 40 consecutive children with invasively diagnosed I/HPAH or CHD-APAH and 117 relatives. Assessment of family members, pedigree analysis and systematic screening for mutations in TGFß genes were performed.
Five mutations in the bone morphogenetic protein type II receptor (BMPR2) gene, 2 Activin A receptor type II-like kinase-1 (ACVRL1) mutations and one Endoglin (ENG) mutation were found in the 29 I/HPAH children. Two mutations in BMPR2 and one mutation in ACVRL1 and ENG, respectively, are described for the first time. In the 11 children with CHD-APAH one BMPR2 gene mutation and one Endoglin gene mutation were found. Clinical assessment of relatives revealed familial aggregation of the disease in 6 children with PAH (HPAH) and one CHD-APAH patient. Patients with mutations had a significantly lower PVR.
Mutations in different TGFß genes occurred in 8/29 (27.6%) I/HPAH patients and in 2/11 (18.2%) CHD-APAH patients and may influence the clinical status of the disease. Therefore, genetic analysis in children with PAH, especially in those with I/HPAH, may be of clinical relevance and shows the complexity of the genetic background.
KeywordsPulmonary hypertension Congenital heart disease Genetics Children Bone morphogenetic protein receptor 2
Pulmonary arterial hypertension (PAH) is a very rare disease in childhood and can occur idiopathic (IPAH), heritable (HPAH) or associated with various diseases (APAH) including congenital heart defect (CHD-APAH) . As soon as familial aggregation or a genetic defect has been identified in IPAH patients they will be classified as HPAH. The true incidence of IPAH, HPAH or CHD-APAH has not yet been established . However, estimates are around 2.2 new cases per million per year in the general population  suggesting that a few hundred children are affected in Germany. Children with I/HPAH can have similar clinical presentation as CHD-APAH patients with identical histological findings including plexiform lesions .
I/HPAH and CHD-APAH are the most frequent cause for PAH in children . The classification of paediatric patients into these groups is difficult in some cases because they often present with multiple symptoms and clinical manifestations . Furthermore, PAH in infancy is frequently associated with genetic syndromes . In 13% of children with pulmonary hypertension chromosomal anomalies such as Trisomy 21 are reported .
It is well known that genetic factors predispose some individuals to develop PAH . Especially heterozygous mutations in the bone morphogenetic protein receptor type II (BMPR2) gene on chromosome 2q33 were found in > 70-80% of adult PAH patients with familial history of disease [8–12]. In sporadic IPAH patients without reported familial history of the disease and in children, BMPR2 mutations were identified much less frequently (in 10-40% of cases [9, 13–15]). BMPR2 mutations are even less common in patients with CHD-APAH. Therefore, an additional genetic background has been postulated .
Previous studies suggested that adult BMPR2 mutation carriers are younger at diagnosis with a more severe hemodynamic compromise [12, 17]. Patients carrying an activin A receptor type II-like 1 (ACVRL1) mutation have been characterized to be even younger at diagnosis and death, compared to patients with BMPR2 mutations or without mutations . Similar results have been seen in a mixed cohort with 15 adult and 8 paediatric mutation carriers . There are no correlation studies yet comparing genetic and clinical findings especially in children with PAH. Two recent studies have identified mutations in the ACVRL1 (also known as ALK1) gene in several paediatric I/HPAH cases [14, 19]. In a child with PAH followed by the development of heritable hemorrhagic telangiectasia (HHT) a mutation in the Endoglin (ENG) gene has been found . Very recently two mutations in the SMAD9 gene were reported in children diagnosed with HPAH [21, 22]. Thus, PAH in infancy seems to have a heterogeneous genetic background. Until now, only a few studies investigated the prevalence of mutations in the genes participating in the TGFß signalling pathway in children systematically. They consisted of small numbers of paediatric PAH patients and predominantly the BMPR2 gene was analysed. The aim of this study was to perform a broad and systematic screening for mutations in BMPR2, ACVRL1, ENG, SMAD1, SMAD5 and SMAD9 genes and to compare clinical and genetic findings in a German cohort of children affected with I/HPAH and CHD-APAH.
Forty unrelated children under the age of 14 years participated in this study. The diagnoses I/HPAH and CHD-APAH were established at the participating PH centers according to current guidelines [1, 23]. In all patients a detailed family history was obtained and a pedigree was constructed. Relatives of index patients underwent detailed clinical examination as described previously [16, 24]. All index patients underwent a detailed clinical work up including right heart catheterization and acquisition of age at onset and age at diagnosis. Their parents gave written informed consent for this study, which was approved by the Ethics Committee of the University of Heidelberg.
Molecular genetic analysis
Genomic DNA was extracted from peripheral blood leukocytes of patients and relatives. The entire coding regions and the exon/intron boundaries of the BMPR2, ACVRL1, ENG, SMAD1, SMAD5 and SMAD9 genes were PCR amplified followed by denaturing high-performance liquid chromatography (DHPLC) as previously described  and/or direct sequenced using BigDye Terminator Kit v1.1 and the ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA). In mutation carriers all first degree relatives, if available, were investigated for the mutation identified in the index patient. Primers and amplification procedures are available upon request. Pathogenicity of identified sequence alterations was assessed by use of the in silico prediction programs “PolyPhen” , and “MutationTaster” , “SIFT” , and Alamut v2.2 (Interactive Biosoftware, ). For detection of whole exonic deletions /duplications the Multiplex Ligation-dependant Probe Amplification (MLPA) technique was applied according to the manufacturer’s instructions (MRC-Holland, Amsterdam).
Hemodynamic values are given as mean values ± standard deviations and 95% confidence intervals. We compared I/HPAH with CHD-APAH and mutation carriers vs. non carriers, respectively, with respect to baseline characteristics and hemodynamic parameters by two-tailed students t-test and Chi-square tests using SPSS 20 (IBM SPSS Statistics V20 IBM Corporation). P values below 0.05 were considered statistically significant.
Identification of mutations
Clinical and genetic characteristics of mutation carriers
Positive family history
Type of mutation
FM clinically assessed
Unaffected FM carrying mutation
c.419-?_621 + ?del
c.1297C > T (p.Q433X)
1 (n. a.)
missense (de novo)
c.1472 G > A (p.R491Q)
c.2668DelA (p.R890GfsX6) *
c.419-10 T > C *#
c.950 T > C (p.I317T) *
yes (HHT + HPAH)
c.1451 G > A (p.R484Q)
2 (one HHT)
c.640 G > A (p.G214S)
CHD-APAH (VSD); Fetal alcohol syndrome
c.1-?_76 + ?del
3 (all †, not tested)
CHD-APAH (ASDII); Congenital hip dislocation
c.1633 G > A (p.G545S)
The two mutations identified in ENG (1 in CHD-APAH and one in IPAH) were previously described in patients with HHT [29, 30]. Both, patients and their mutation positive but unaffected family members in our cohort did not show any sign of HHT. In five of I/HPAH and in two CHD-APAH patients the identified mutations were also identified in asymptomatic family members (in 6 parents, 3 grandparents, 1 aunt and 1 sister). No mutations were identified in any of the analysed SMAD genes.
Table 1 lists all identified mutations, the type of alteration, their location in the gene, gender, the age at diagnosis, and clinical classification. New identified mutations of the investigated genes are indicated by asterisks. Common and rare polymorphisms without disease relevance have also been detected in all investigated genes (data not shown).
Distribution and frequency of mutations
Clinical and hemodynamic characteristics
Clinical characteristics at diagnosis
Baseline and hemodynamic parameters
Mean ± SD
95% CI for the mean
Mean ± SD
95%CI for the mean
Mean ± STD
95%CI for the mean
Mean ± STD
95%CI for the mean
Age of onset at first symptoms (years)
4.4 ± 3.9
4.5 ± 3.9
5.3 ± 4.1
4.1 ± 3.8
Age at diagnosis by RHC (years)
5,2 ± 4.3
6.9 ± 4.7
7.1 ± 4.1
5.6 ± 4.5
Heart rate per minute
98 ± 35
94 ± 15
93.4 ± 21.3
97.8 ± 31.3
Oxygen Saturation (%)
95.0 ± 6.5
81.8 ± 31.8
97.3 ± 2.2
88.3 ± 22.7
PASP (mm Hg)
87.3 ± 49.4
82.1 ± 23.8
64.5 ± 5.7
90.5 ± 45.4
PADP (mm Hg)
38.9 ± 26.1
39.8 ± 16.1
25.0 ± 11.1
43.0 ± 24.0
PAMP (mm Hg)
58.0 ± 33.0
55.5 ± 16.3
43.6 ± 6.6
60.8 ± 31.0
PCWP (mm Hg)
6.9 ± 3.3
6.2 ± 3.5
6.0 ± 4.4
6.9 ± 3.1
SASP (mm Hg)
93.7 ± 14.1
93.7 ± 13.0
94.6 ± 8.7
93.5 ± 14.5
SADP (mm Hg)
52.1 ± 16.2
53.1 ± 6.8
58.0 ± 5.4
51.1 ± 14.0
Cardiac Index (L/min/m 2 )
3.3 ± 1.1
3.7 ± 0.8
3.6 ± 1.1
3.3 ± 1.0
PVRI (Wood U*m 2 )
18.6 ± 16.1
12.9 ± 6.2
8.5 ± 2.5
19.4 ± 15.2
PVR (dyn*s*cm −5 )
2012.2 ± 1788.8
1795.4 ± 1038.8
927.0 ± 284.4
2244.8 ± 1692.5
The results of the study indicate that the proportion of genetic alterations in children with various forms of PAH is higher than previously thought and is related to several different genes of the TGFß pathway. Mutations of the BMPR2, ACVRL1, and ENG gene, respectively, occurred in 8 out of 29 (27.5%) of I/HPAH patients and even in 2 of 11 patients (18.2%) with CHD-APAH. Children carrying a mutation had a significantly lower PVR than non carriers. Two BMPR2 and one ACVRL1 mutation detected in this study have not been described before. Genetic analysis in children with various forms of PAH may be of clinical relevance and shows the complexity of the genetic background in childhood.
Prevalence of gene alterations in children with I/HPAH
The prevalence of the here identified mutations in 27.5% of I/HPAH patients in the BMPR2, ACVRL1 and ENG genes is similar as previously reported. In 22% of 18 I/HPAH-children Harrison et al. found mutations in these 3 genes . Rosenzweig et al. found in 10% of patients BMPR2 mutations . In contrast to these 3 genes sequence alterations of the SMAD genes (SMAD1, SMAD5 and SMAD9) seem to be a rare event in adult or paediatric PAH patients (<2%) with unclear functional significance . In this study we identified no mutation in any of the SMAD genes, but 3 rare polymorphisms in SMAD9 in 3 I/HPAH patients.
Genetic findings in children with CHD-APAH and classification
The findings of this study (mutations in 18.2%) confirm that gene defects play also a role in CHD-APAH-patients. However, BMPR2 mutations have been a rare finding in CHD-APAH and occurred in only 6% of cases of a mixed cohort of adults and children . In our CHD-APAH-patient we found a deletion of the first exon of the BMPR2 gene which has been previously observed only in I/HPAH [32, 33]. Although such deletions are predicted to cause an altered translation, their penetrance is variable and clinically unaffected mutation carriers have also been reported  and have been seen in the sister of our index patient. HPAH and CHD-APAH are simultaneously present in this family. Thus, the classification in HPAH and CHD-APAH according to the guidelines [1, 34] seems to be difficult in this case since both forms can occur in one patient.
Mutations of ACVRL1/ENG and HHT in childhood
This study shows that ACVRL1 and ENG mutations can cause the development of severe PAH in childhood, without any symptoms or familial history of HHT. Wide intrafamilial phenotypic variations were previously observed in carriers of a mutation at position 484 . Some of the mutation carriers in these families showed symptoms of HHT, others of pulmonary hypertension and one a combination of both phenotypes , as was seen in our family with altered amino acid at this position (p.R484Q). The novel mutation p.I317T identified in patient A3385 was also present in three unaffected family members. Neither the index patient nor the mutation carriers in this family showed any clinical signs of HHT and occurrence of HHT was also not reported in the family history.
In our cohort we have detected two missense mutations in the ENG gene: one in a patient with IPAH (A15836, p.G214S), and one in a patient with CHD-APAH (D3783). ENG mutations are quite common in HHT patients and both mutations have previously been described in patients with HHT only [29–31]. In our patients neither the index patient nor any of the mutation positive family members showed any clinical signs of HHT.
The ENG mutations identified in a CHD-APAH patient and in an IPAH patient without phenotypic appearance of HHT sheds new light on the variability of the phenotype caused by defects in TGFß pathway genes. Both mutations lead to an exchange from a highly conserved glycine residue to a serine residue but are located on different sites of the protein: p.G214S at the N-terminal and p.G545S at the C-terminal part of the endoglin/CD105 domain. They are both considered to be damaging predicted by PolyPhen .
Beside the here identified genetic defects in children with I/HPAH and CHD-APAH there are most likely further not yet identified genetic factors, in some families possibly inherited in a recessive mode of inheritance as previously suggested .
Clinical relevance of genetic alterations
We compared hemodynamic parameters between the 10 mutation carriers and 30 non carriers. In our study, patients with mutation had a significantly lower PVR than patients without mutation. Due to the small number of patients we cannot exclude that this difference could have been accidentally occurred particularly with respect to the not significantly different PVRI. Rosenzweig et al.  found no significant differences in PVRI between mutation carriers and non carriers as well. These comparisons are anyhow difficult with respect to the genetic heterogeneity in this population.
I/HPAH vs. CHD-APAH
In this study we did not find significant differences in hemodynamic parameters or age at onset between I/HPAH and CHD-APAH patients. This is in contrast to data from Barst et al.  and Hill et al.  who both found a significantly higher PVRI and an older age at onset of the disease in I/HPAH patients. Again this might be due to the relatively small numbers of patients. Further studies with larger cohorts are needed to investigate the differences between I/HPAH and CHD-APAH.
In conclusion, mutations in different TGFß genes occurred in 8 out of 29 I/HPAH patients and 2 out of 11 CHD-APAH-patients and may influence the clinical status of the disease. Therefore, genetic analysis in children with PAH may be of clinical relevance and shows the complexity of the genetic background.
- Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219–1263.PubMedView Article
- Barst RJ, Ertel SI, Beghetti M, Ivy DD: Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011, 37:665–677.PubMedView Article
- Fraisse A, Jais X, Schleich JM, di Filippo S, Maragnes P, Beghetti M, Gressin V, Voisin M, Dauphin C, Clerson P, et al.: Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010, 103:66–74.PubMedView Article
- Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al.: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43:5S-12S.PubMedView Article
- Haworth SG, Hislop AA: Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006. Heart 2009, 95:312–317.PubMedView Article
- van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, Blom NA, Backx A, Berger RM: Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 2009, 155:176–182. e171PubMedView Article
- Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ: Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012, 379:537–546.PubMedView Article
- Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, Janssen B, Koehler R, Seeger W, et al.: Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006, 27:121–132.PubMedView Article
- Koehler R, Grunig E, Pauciulo MW, Hoeper MM, Olschewski H, Wilkens H, Halank M, Winkler J, Ewert R, Bremer H, et al.: Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. J Med Genet 2004, 41:e127.PubMedView Article
- Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M: Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008, 177:1377–1383.PubMedView Article
- Austin ED, Loyd JE, Phillips JA: Genetics of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009, 30:386–398.PubMedView Article
- Pfarr N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, Ehlken N, Tiede H, Olschewski H, Reichenberger F, Ghofrani AH, et al.: Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res 2011, 12:99.PubMedView Article
- Morisaki H, Nakanishi N, Kyotani S, Takashima A, Tomoike H, Morisaki T: BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension. Hum Mutat 2004, 23:632.PubMedView Article
- Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, Aldred MA, Trembath RC: Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005, 111:435–441.PubMedView Article
- Rosenzweig EB, Morse JH, Knowles JA, Chada KK, Khan AM, Roberts KE, McElroy JJ, Juskiw NK, Mallory NC, Rich S, et al.: Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008, 27:668–674.PubMedView Article
- Grunig E, Koehler R, Miltenberger-Miltenyi G, Zimmermann R, Gorenflo M, Mereles D, Arnold K, Naust B, Wilkens H, Benz A, et al.: Primary pulmonary hypertension in children may have a different genetic background than in adults. Pediatr Res 2004, 56:571–578.PubMedView Article
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al.: Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023–1030.PubMedView Article
- Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, et al.: Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010, 181:851–861.PubMedView Article
- Fujiwara M, Yagi H, Matsuoka R, Akimoto K, Furutani M, Imamura S, Uehara R, Nakayama T, Takao A, Nakazawa M, Saji T: Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008, 72:127–133.PubMedView Article
- Mache CJ, Gamillscheg A, Popper HH, Haworth SG: Early-life pulmonary arterial hypertension with subsequent development of diffuse pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia type 1. Thorax 2008, 63:85–86.PubMedView Article
- Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R: A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009, 46:331–337.PubMedView Article
- Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, Bradshaw TY, Southgate L, Lee GJ, Jackson I, et al.: Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011,32(12):1385–1389.PubMedView Article
- Grunig E, Barner A, Bell M, Claussen M, Dandel M, Dumitrescu D, Gorenflo M, Holt S, Kovacs G, Ley S, et al.: Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. Int J Cardiol 2011,154(Suppl 1):S3–12.PubMedView Article
- Grunig E, Janssen B, Mereles D, Barth U, Borst MM, Vogt IR, Fischer C, Olschewski H, Kuecherer HF, Kubler W: Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000, 102:1145–1150.PubMedView Article
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248–249.PubMedView Article
- Schwarz JM, Rodelsperger C, Schuelke M, Seelow D: MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010, 7:575–576.PubMedView Article
- Ng PC, Henikoff S: SIFT: predicting amino acid changes that affect protein function. Nucl Acids Res 2003,31(3):3812–3814.PubMedView Article
- Interactive Biosoftware. http://www.interactive-biosoftware.com
- Brakensiek K, Frye-Boukhriss H, Malzer M, Abramowicz M, Bahr MJ, von Beckerath N, Bergmann C, Caselitz M, Holinski-Feder E, Muschke P, et al.: Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia. Clin Genet 2008, 74:171–177.PubMedView Article
- Mei-Zahav M, Letarte M, Faughnan ME, Abdalla SA, Cymerman U, MacLusky IB: Symptomatic children with hereditary hemorrhagic telangiectasia: a pediatric center experience. Arch Pediatr Adolesc Med 2006, 160:596–601.PubMedView Article
- Roberts KE, McElroy JJ, Wong WP, Yen E, Widlitz A, Barst RJ, Knowles JA, Morse JH: BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004, 24:371–374.PubMedView Article
- Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA, Newman J, Williams D, Galie N, et al.: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001, 68:92–102.PubMedView Article
- Aldred MA, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, Galie N, Manes A, Corris P, Simonneau G, et al.: BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006, 27:212–213.PubMedView Article
- Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al.: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43–54.PubMedView Article
- Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, et al.: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001, 345:325–334.PubMedView Article
- Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD: Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012, 125:113–122.PubMedView Article
- Hill KD, Lim DS, Everett AD, Ivy DD, Moore JD: Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. Catheter Cardiovasc Interv 2010, 76:865–873.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.